Aratana Therapeutics (PETX) Announces FDA Approval of NOCITA
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved NOCITA® (bupivacaine liposome injectable suspension) as a local post-operative analgesia for cranial cruciate ligament surgery in dogs. Aratana anticipates Nocita will be commercially available to veterinarians in the fall of 2016.
Nocita is a long-acting, local anesthetic that lasts up to 72 hours post-surgery by releasing bupivacaine over time from multi-vesicular liposomes deposited in the tissue. The therapeutic is administered as a single dose by tissue infiltration during closure of cranial cruciate ligament surgery in dogs.
"We believe Nocita will help transform the way veterinarians control post-operative pain for dogs undergoing cranial cruciate ligament surgery," states Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics. "As our third FDA-approved therapeutic this year, we are pivoting our attention to successfully bringing these therapeutics to market over the coming months."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Merck (MRK) Announces KEYTRUDA Phase 3 KEYNOTE-045 Met Primary Endpoint; Trial Stopped Early
- General Electric (GE) Tops Q3 EPS by 2c; Updates FY16 EPS Outlook
- Alkermes' (ALKS) FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder Mets Primary Endpoint
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot Corp. News, Management Comments
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!